Introduction
Heart failure with preserved ejection fraction (HFpEF) affects approximately 2.7 million adults in the USA alone.
1 Morbidity and clinical course. 4, 5 To better target therapeutic strategies, a more refined characterization of myocardial abnormalities beyond 'normal' left ventricular ejection fraction (LVEF) may prove useful.
Previous resting evaluations of left ventricular (LV) systolic properties in patients with HFpEF have yielded conflicting results. For example, a previous study found that long-axis LV systolic function was impaired by tissue Doppler imaging in a population of patients with impaired diastolic filling compared with normal controls, 6 while another study, by echocardiography and simultaneous cardiac catheterization, found that stroke work and peak positive dP/dt were similar in patients with HFpEF compared with normal controls. 7 These differences are likely related to different populations of patients and differences in technique for evaluating LV systolic properties.
Subclinical resting systolic dysfunction as assessed by global longitudinal strain (GLS) analysis 8, 9 is a potentially useful tool to evaluate LV systolic properties and has key advantages over previous non-invasive techniques. Left ventricular GLS can be rapidly and reproducibly quantified by speckle-tracking echocardiography, which is an ultrasound technology that permits a detailed assessment of myocardial tissue deformation in any direction. 10 Recent data suggest that LV GLS is abnormal in a subset of patients with HFpEF and that impaired LV GLS is associated with higher N-terminal pro-brain natriuretic peptide (NT-proBNP) values. 8, 9 However, the interplay between impaired LV GLS and other markers of the HFpEF clinical syndrome, including diastolic dysfunction, biomarkers associated with myocardial fibrosis, functional class, exercise capacity and patient-centred outcomes such as quality of life assessments has not been established.
We aimed to use data from the PhosphodiesteRasE-5 Inhibition to Improve CLinical Status And EXercise Capacity in Diastolic Heart Failure (RELAX) trial 11 in order to (i) further characterize the prevalence of impaired LV GLS in a contemporary outpatient cohort with objectively defined HFpEF, and (ii) examine the association between impairments in resting LV deformation by GLS and other baseline patient characteristics. We hypothesized that impaired LV GLS would identify those HFpEF patients with worse New York Heart Association (NYHA) symptom class, quality of life and exercise capacity.
Study design

Data source
The study design and results of the RELAX trial were published previously. 11, 12 Briefly, RELAX was a multicentre, randomized, double-blind, placebo-controlled trial that evaluated the effect of sildenafil in patients with chronic, symptomatic HFpEF. The trial was conducted from October 2008 to February 2012 at 26 centres throughout the USA and Canada, and enrolled 216 patients. The primary endpoint of the trial was change in peak oxygen consumption (VO 2 ) from baseline to 24 weeks. Other endpoints in the study included circulating biomarker analysis, 6-min walk distance and quality of life assessments by the Minnesota Living with Heart Failure (MLHF) Questionnaire. 13 The RELAX trial conformed to the principles outlined in the Declaration of Helsinki. The trial was designed by the National Heart, Lung, and Blood Institute (NHLBI)-sponsored Heart Failure Clinical Research Network investigators and was approved by protocol review and data safety monitoring committees as well as each participating site's institutional review board. All patients provided written informed consent before randomization.
Patient characteristics and study definitions/outcome data
Patients enrolled in RELAX had a history of: (i) an LVEF of ≥50% within the past 12 months, and (ii) previous objective evidence of heart failure (such as previous hospitalization because of heart failure or chronic use of a loop diuretic for heart failure and left atrial enlargement by echocardiography). At the time of enrolment, patients also had to have (i) a peak VO 2 of ≤60% of age-and sex-adjusted normal values with a respiratory exchange ratio of ≥1.0 at the time of screening, and (ii) either of the following: elevated natriuretic peptide levels or elevated LV filling pressures by invasive haemodynamic assessment. Evidence of diastolic dysfunction by echocardiography was not required for entry into the study. Patients with a previous history of reduced LVEF (<50%) were excluded from the study.
Echocardiographic assessments and strain analysis
All patients received an echocardiogram at baseline as part of the study protocol. Standard echocardiographic measurements were performed by the Heart Failure Network core echocardiography laboratory (Mayo Clinic) according to the American Society of Echocardiography recommendations 15, 16 and then additional strain analyses were performed in the Duke Echocardiographic Laboratory (Duke University Medical Centre).
Left ventricular mass was calculated using the formula recommended by the American Society of Echocardiography and indexed to body surface area. 15 Left ventricular mass was indexed to height and sex to determine LV hypertrophy. To assess LVEF, we preferentially used biplane Simpson's disc method, but if the definition of LV endocardial border was not satisfactory, then the LVEF was determined visually. End-systolic circumferential wall stress and midwall fractional shortening were calculated using prolate ellipse geometric assumptions. Stroke volume and cardiac index were calculated from the time velocity integral of the pulsed wave Doppler signal of the LV outflow tract flow and area. Early diastolic medial mitral annular tissue velocity (medial e ′ ), early mitral inflow deceleration time, and the ratio of the early transmitral flow velocity (E) to e ′ (E/e ′ ) were used to estimate LV relaxation, LV stiffness, and LV filling pressure, respectively. Left atrial volume was calculated using the formula recommended by the American Society of Echocardiography and indexed to body surface area. 15 Pulmonary artery systolic pressure was calculated from the peak tricuspid regurgitant velocity and the estimated right atrial pressure using the modified Bernoulli equation. Resting systolic blood pressure was measured at the time of echocardiography. End-systolic pressure was estimated as systolic pressure times 0.9, and the effective arterial elastance was then estimated as end-systolic pressure divided by stroke volume, as described previously. 17 Systemic arterial compliance was estimated by the stroke volume to pulse pressure ratio, and systemic vascular resistance was estimated by mean arterial pressure divided by cardiac output × 80. 18 For strain analysis, all echocardiograms were transferred in DICOM (Digital Imaging and Communications in Medicine) format from Philips Xcelera (Philips Medical Systems, Eindhoven, the Netherlands) to a vendor-independent software package (2D Cardiac Performance Analysis version 4.5; TomTec Imaging Systems, Unterschleissheim, Germany) at a frame rate ≥30/s. Retrospective speckle-tracking longitudinal strain assessments on two-dimensional images have been validated using TomTec software, even when the original study was not intended for this purpose. 19 All analyses were performed by a single experienced operator blinded to other patient characteristics. Longitudinal strain assessments for the left ventricle were performed in the apical four-, three-, and two-chamber views. For speckle tracking, the endocardial border was manually traced in end systole. The integrity of speckle tracking was ascertained visually. In the case of insufficient tracking, manual correction of the endocardial tracing was attempted and if still unsatisfactory the segment was excluded from the analysis. For patients with atrial fibrillation, the average of 10 measurements from different cardiac cycles was used. Longitudinal strain was calculated as the change in length divided by the original length of the speckle pattern over the cardiac cycle and expressed as a percentage; myocardial longitudinal lengthening was represented as positive strain and shortening as negative strain. Thus, better systolic performance as assessed by LV GLS is noted by numbers of greater magnitude with a negative sign to indicate myocardial longitudinal shortening. Global longitudinal strain for the entire left ventricle was averaged from the results of 18 segmental peak systolic strains. Normal LV GLS was defined as ≤ −16%, based on existing literature where normal LV GLS varies from −15.9% to −22.1%. 20 To examine intra-observer reliability, we reassessed LV longitudinal strain assessments in a random sample of 30 patients. The correlation coefficients were 0.98, 0.96, and 0.97 for LV longitudinal strain assessments in the apical four-, three-, and two-chamber views, respectively. The correlation coefficient was 0.99 for LV GLS.
Statistical methods
We summarized baseline characteristics and echocardiographic assessments for patients enrolled in the RELAX trial and stratified by tertile of LV GLS. Continuous variables were reported as medians and 25th and 75th percentiles; categorical variables were reported as counts and percentages. We tested for differences between the groups using chi-square tests for categorical variables and Kruskal-Wallis tests for continuous variables. Linear regression models were used to evaluate the relationship between LV GLS and biomarkers of interest, peak VO 2 Spearman rank correlation analysis were performed to assess dependence. In an exploratory analysis, Cox proportional hazards regression was used to evaluate the relationship between LV GLS and a composite endpoint of time to death or all-cause hospitalization. A two-sided P-value <0.05 was considered statistically significant for all analyses. We analysed the data using SAS software (version 9.2; SAS Institute, Cary, NC, USA).
Results
Of the 216 patients enrolled in RELAX, 187 (87%) were included in our analysis, 17 (7.9%) echocardiograms could not be obtained for secondary analysis and 12 of the remaining 199 echocardiograms (6.0%) had images that were suboptimal for strain analysis ( Figure 1) . The baseline median LV GLS was −14.6% (25th and 75th percentile: −17.0 and −11.9%, respectively) and abnormal (defined as ≥ −16% based on existing literature) 20 in 122/187 (65%) patients.
The baseline characteristics of patients enrolled in the RELAX trial stratified by tertile of LV GLS are displayed in Table 1 . We observed no notable numerical or statistical differences in the three groups in terms of demographic or medical history variables other than female sex, which was most common in patients with the tertile with the best LV GLS, and history of atrial arrhythmias, which were least common in patients with the tertile of best LV GLS. New York Heart Association classification was similar across the three groups. Quality of life as assessed by MLHF scores was statistically different (p = 0.042) between the three groups but in a non-linear fashion (Figure 2 ). Both NT-proBNP and collagen III N-terminal propeptide (PIIINP) were associated with LV GLS where the tertile of best systolic performance was associated with lower NT-proBNP and PIIINP values (P = 0.008 and P = 0.001, respectively). The linear relationships are displayed in Figure 2 for PIIINP and for the log-transformed values of NT-proBNP. We observed no association between tertile of LV GLS and 6-min walk distance, peak VO 2 or expiratory minute ventilation/carbon dioxide excretion (VE/VCO 2 ) slope.
The baseline echocardiographic assessments of patients enrolled in the RELAX trial by tertile of LV GLS are displayed in Table 2 . We observed no association between tertile of LV GLS and LV hypertrophy or end-systolic circumferential wall stress. Patients with the best LV GLS were associated with higher midwall fractional shortening (P = 0.028) and higher E-wave deceleration time (P = 0.002). There was also a trend towards best LV GLS and small left atrial volumes (p = 0.081) and E/A ratios (P = 0.068). Systolic blood pressure during the echocardiogram was similar across the three groups, as was pulse pressure. However, effective arterial elastance was highest in patients with the best LV GLS.
The relationships between LV GLS and selected baseline patient characteristics are displayed in Figure 2 . We observed a linear association between LV GLS and PIIINP (r = 0.19, P = 0.009) and log-transformed NT-proBNP (r = 0.29, P < 0.001) but no linear relationship with peak VO 2 or peak MLHF score. For the analysis of PIIINP, one outlier value was excluded because of concern over error in measurement or data entry (50 μg/L). In a sensitivity analysis, we repeated the analysis and included this value and noted minimal change in the relationship (r = 0.16, P = 0.026). We also repeated this analysis using a Spearman rank correlation analysis and noted a similar linear relationship between LV GLS and PIIINP (r = 0.26, P < 0.001).
In an exploratory analysis, we also assessed the relationship between LV GLS and a composite endpoint of time to death or all-cause hospitalization. In the RELAX trial, there were 35 events and these were distributed evenly across the three groups with no relationship between the tertiles of LV GLS and this composite outcome (P = 0.952).
Discussion
In the present study, we examined the prevalence of LV GLS in a population of patients with well-profiled, objectively defined HFpEF, and assessed for associations of LV GLS with other baseline characteristics. To our knowledge, this is the largest study of patients with . HFpEF to examine the association between LV GLS and functional status and quality of life. Using a conservative definition of impaired LV GLS, 20 we found that impaired LV GLS was common (present in 65% of the study population). Consistent with previous studies, LV GLS was associated with biomarkers associated with increased wall stress. 8, 9, 21 We also found an association with increased fibrosis, as measured by a biomarker of collagen synthesis (i.e. circulating PIIINP) and with severity of diastolic dysfunction, as measured by echocardiography. Contrary to our hypothesis, we found no association with LV GLS and NYHA symptom class, functional capacity as assessed by 6 minute walk test or cardiopulmonary exercise test, or quality of life scores. Impaired LV GLS reflects fundamental myocardial abnormalities among the majority of HFpEF patients closely linked to objective measures of impaired ventricular filling, myocardial fibrosis, and increased wall stress, but not to functional capacity or quality of life. Our findings build upon other recent studies of LV GLS in patients with HFpEF. Investigators from PARAMOUNT (Prospective Comparison of ARNI with ARB on Management of Heart 2 (n = 62)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Failure With Preserved Ejection Fraction Trial) 8 found that LV GLS was impaired relative to both normal controls and patients with hypertensive heart disease, and described an independent association with LV GLS and higher NT-proBNP levels. Investigators from the University of Hull, UK, also found a linear relationship between log-transformed NT-proBNP and LV GLS in outpatients with chronic heart failure and LVEF ≥50%. 9 In our analysis, we found a similar relationship with NT-proBNP levels and present these data as both tertiles of LV GLS and log-transformed NT-proBNP. In addition to representing abnormal wall stress, our findings also suggest that abnormal LV GLS is associated with biomarker evidence of increased collagen synthesis. Collectively, these three retrospective observational studies suggest that patients with HFpEF and abnormal myocardial deformation, as assessed by speckle-tracking strain analysis, may identify a patient profile with fundamental myocardial abnormalities that may be amenable to therapeutic interventions intended to reduce LV wall stress and fibrosis, including beta-blockers and . Data from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial 24 demonstrated that abnormal LV GLS also has prognostic implications in patients with HFpEF. Patients enrolled in the TOP-CAT trial with abnormal baseline longitudinal strain, defined as > −15.8%, were more likely to experience the primary composite outcome of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest [adjusted hazard ratio (HR) 2.14; 95% confidence interval (CI) 1.26-3.66; P = 0.005]. Our sample size is too small to draw conclusions about the prognostic relevance of impaired LV GLS and its performance relative to other variables associated with outcomes in patients with HFpEF, including NT-proBNP. 25 In the present study, abnormal resting LV GLS was, surprisingly, not associated with symptoms, quality of life, or exercise capacity. There are many possible reasons for this, one of which is the robust literature supporting the idea that symptoms and functional capacity are better evaluated with assessments of systolic and diastolic functional reserve during exercise; this may be more informative than assessments of LV GLS at rest in patients with HFpEF. 26 -29 In addition, patients with the best tertile of LV GLS had the highest effective arterial elastance. Previous studies have demonstrated the importance of arterial stiffness and ventricular-arterial coupling in patients with HFpEF. 30 For example, a recent study of HFpEF patients hospitalized with acute heart failure used pulse pressure as an assessment of arterial stiffness and noted that patients with a pulse pressure >75 mmHg had higher BNP values and E/e ′ as well as increased risk of future cardiovascular and heart failure-related events compared with those with a pulse pressure of 45-74 mmHg. 31 Finally, a more provocative hypothesis is that decreased functional capacity and quality of life in patients with HFpEF may be more reflective of extracardiac mechanisms and co-morbid conditions contributing to the clinical syndrome of HFpEF than intrinsic myocardial abnormalities. For example, in a previous ancillary study of the RELAX trial, age, sex, body mass index, haemoglobin, and chronotropic reserve explained 64% of the variability observed in peak VO 2 in a multivariable analysis.
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Measures of resting LV systolic, LV diastolic, and vascular function were either modestly associated with peak VO 2 or had no association with it. The hypothesis that decreased functional capacity and quality of life in patients with HFpEF may be more reflective of extracardiac mechanisms and co-morbid conditions requires additional study and may have implications not only for the diagnosis and treatment of patients with HFpEF but also for endpoints used in HFpEF therapeutic trials.
It is important to note that the findings of the present study contrast with findings from an analysis of 37 patients with HFpEF at Oslo University Hospital, Norway. 32 In that study, LV GLS was correlated with peak VO 2 in a multivariable analysis, −0.80 mL/kg.min (−1.49 to −0.11, P = 0.02). The different findings may be related to differences in patient populations. Patients enrolled in the Oslo study were younger (mean age 58 ± 11 years), with higher LV GLS (−17.5 ± 3.2%), lower NT-proBNP values (115 ± 164 pmol/L), and higher peak VO 2 (20.1 ± 6.9 mL/kg.min).
Limitations
The present study has some limitations including the fact that it was a retrospective analysis from a clinical trial and the patients met specific entry criteria. For example, patients enrolled in RELAX were required to have an abnormal peak VO 2 . These patients may not be representative of all patients with HFpEF though patients with abnormal peak VO 2 are more likely to be symptomatic. In addition, we assessed LV GLS in resting echocardiograms, but evaluations of myocardial abnormalities during exercise may be more informative for symptom class, quality of life and exercise capacity. In addition, LV GLS could not be calculated on 6% of the echocardiograms because of limited image quality or inadequate image acquisition. Finally, the number of events in the study was . small and therefore it is difficult to draw conclusions on the association of LV GLS and clinical outcomes.
Conclusions
Abnormal myocardial deformation is common in the majority of-although not all-patients with well-profiled, objectively defined HFpEF. Left ventricular GLS has a modest association with biomarkers of wall stress and collagen synthesis and with severity of diastolic dysfunction. These data suggest that LV GLS reflects fundamental myocardial abnormalities linked to objective measures of impaired ventricular filling, myocardial fibrosis and increased wall stress, although the clinical application of speckle-tracking strain analysis in patients with HFpEF requires further study. Impaired resting LV GLS is not associated with functional class, quality of life, or exercise capacity, and other processes, such as extracardiac mechanisms, may be responsible for these aspects of the HFpEF syndrome.
Funding
This study was supported by National Institutes of Health grants U10HL084904 (Duke Clinical Research Institute, the data coordinating centre). Conflict of interest: none declared.
